<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234923</url>
  </required_header>
  <id_info>
    <org_study_id>FRAN-03-001</org_study_id>
    <secondary_id>EUDRACT: 2004-816-24</secondary_id>
    <secondary_id>MONARK</secondary_id>
    <nct_id>NCT00234923</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients</brief_title>
  <acronym>MONARK</acronym>
  <official_title>A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen Versus Lopinavir/Ritonavir in Combination With Lamivudine/Zidovudine in Antiretroviral Naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to obtain a preliminary assessment of the antiviral
      activity and tolerability of Kaletra single agent therapy as initial treatment for HIV
      infection, relative to a Kaletra three drug standard of care reference arm
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiviral efficacy by HIV RNA</measure>
    <time_frame>48 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm comparisons: CD4 evolution, occurrence of HIV protease and RT mutation, occurrence of AIDS clinical events, safety of NRTI-sparing vs. a PI with 2 NRTIs regimen: clinical and biological tolerance, patient's adherence and quality of life.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess in the LPV/r single-drug regimen arm: virological control, CD4 evolution, safety</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kaletra Monotherapy: lopinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir</intervention_name>
    <description>400 mg lopinavir/ 100 mg ritonavir, BID</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ABT-378</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine/zidovudine</intervention_name>
    <description>300mg lamivudine/150mg zidovudine, BID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antiretroviral naïve

          -  HIV RNA &lt;100,000 copies/mL

          -  CD4 cell count &gt;100 cells/mL at screening

          -  with Karnofsky Score &gt; 70

          -  If female,

               -  non-pregnant and

               -  not breastfeeding

          -  No AIDS opportunistic infection within 30 days of screening

        Exclusion Criteria:

          -  Subject with an HIV primo-infection status

          -  Recent history of drug and/or alcohol abuse

          -  History of psychiatric illness

          -  If presence of the following mutations :

               -  in the protease : one among 32,47,48,50,82,84,90

               -  OR more than 3 mutations from the other points of the LPV mutation
                  score:10,20,24,46,53,54,63,71

               -  in the reverse transcriptase : 215 or 184.

          -  If abnormal laboratory results such as :

               -  Hb&lt;8 g/dl

               -  Absolute neutrophil count&lt;750 cells/µl

               -  Platelet count&lt;50 000/ml
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gerard Goldfarb, Abbott France Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Kaletra</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

